MORE►
Michael McFadden
[Image: sudok1/istockphoto]
Alpha Cognition Inks $44M Deal With China’s CMS to License Alzheimer’s Drug in Asia and Beyond
by David Seeley | Jan 9, 2025
Alpha Cognition’s Alzheimer’s oral therapy ZUNVEYL, FDA-approved in July, targets U.S. launch in Q1 2025 as the company boosts its commercialization team with five new hires.
by Lance Murray |
Jul 29, 2024
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
MORE►
by David Seeley |
Dec 13, 2023
Based in Vancouver with a North Texas office in Frisco, Alpha Cognition said its novel oral tablet ALPHA-1062 is designed for the treatment of people with mild to moderate Alzheimer's disease. The company was honored at the recent BioNTX iC3 Summit as one of eight "Rising Stars."
MORE►
